Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

70.56USD
12 Nov 2018
Change (% chg)

$-2.23 (-3.06%)
Prev Close
$72.79
Open
$72.70
Day's High
$72.89
Day's Low
$70.40
Volume
1,472,936
Avg. Vol
1,613,840
52-wk High
$74.15
52-wk Low
$54.32

Select another date:

Fri, Oct 26 2018

Photo

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Abbott Labs quarterly profit falls on higher tax expense

Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

UPDATE 1-Abbott Labs quarterly profit falls on higher tax expense

Oct 17 Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

Abbott Labs quarterly profit falls 6.6 pct on tax expense

Oct 17 Diversified healthcare company Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

Abbott Labs raises 2018 earnings forecast, shares hit record high

Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.

UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high

* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)

Abbott Labs tops profit estimates, raises full-year earnings forecast

July 18 Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.

Allergan appoints former Abbott executive to its board

Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

Select another date: